The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comparative effectiveness of gemcitabine plus cisplatin (GC) versus methotrexate, vinblastine, doxorubicin, plus cisplatin (MVAC) as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC).
Matt D. Galsky
No relevant relationships to disclose
Lauren Christine Harshman
No relevant relationships to disclose
Simon J. Crabb
No relevant relationships to disclose
Yu-Ning Wong
No relevant relationships to disclose
Evan Y. Yu
No relevant relationships to disclose
Simon Chowdhury
No relevant relationships to disclose
Thomas Powles
No relevant relationships to disclose
Sumanta Kumar Pal
No relevant relationships to disclose
Erin L. Moshier
No relevant relationships to disclose
Sylvain Ladoire
No relevant relationships to disclose
Syed A. Hussain
No relevant relationships to disclose
Neeraj Agarwal
No relevant relationships to disclose
Ulka N. Vaishampayan
No relevant relationships to disclose
Federica Recine
No relevant relationships to disclose
Dominik Berthold
No relevant relationships to disclose
Andrea Necchi
No relevant relationships to disclose
Christine Theodore
No relevant relationships to disclose
Matthew I. Milowsky
No relevant relationships to disclose
Joaquim Bellmunt
No relevant relationships to disclose
Jonathan E. Rosenberg
No relevant relationships to disclose